All Transactions - Bryan, Garnier & Co

Our transactions

Bryan, Garnier & Co offers a complete range of investment banking services, from growth financing to mergers and acquisitions.

Bryan, Garnier & Co acts as Joint Bookrunning Manager on Celyad’s $20 million global equity offering

Bryan, Garnier & Co acts as Joint Bookrunner to Genfit on its $155.4 million Nasdaq Initial Public Offering

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for MedinCell’s €30 million Euronext Paris IPO

Bryan, Garnier & Co acts as Joint Bookrunner on Materialise’s USD45 million Follow–On Equity Offering on Nasdaq

Bryan, Garnier & Co acts as Sole Bookrunner on ASIT biotech EUR12 million Convertible Bond Placement

Bryan, Garnier & Co acts as Co-Manager on Canopy Growth’s benchmark CAD500 million Convertible Bond New Issue

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Voluntis’ IPO, the first ever listing of a digital therapeutics company raising EUR30.1 million

Bryan, Garnier & Co acts as Lead Manager on Medigene’s EUR48.3 million offering

Bryan, Garnier & Co acts as Joint Global Coordinator on Celyad’s EUR46.1 million global equity offering

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Medartis’ IPO CHF142.6 million on SIX Swiss Exchange

Bryan, Garnier & Co part of bulge bracket syndicate for DBV $150 million Follow-on

Bryan, Garnier & Co advises Bone Therapeutics on its €19.45 million convertible bond placement

Bryan Garnier & Co acts as Global Coordinator for Biom’Up’s financing representing a total amount of more than €40 million

Bryan, Garnier & Co acts as Co-manager for Ablynx Nasdaq IPO raising USD 230 million

Bryan Garnier & Co acts as Sole Global Coordinator for Biom’Up’s landmark Euronext IPO, raising up to €44 million including greenshoe

Bryan, Garnier & Co acts as Joint Bookrunner of a private placement with US and European Investors raising €18 Million for Oryzon

Upon pricing its landmark IPO on Euronext Paris led by Sole Global Coordinator Bryan, Garnier & Co, Symetis is acquired by Boston Scientific for USD 435 million

Bryan, Garnier & Co announces the successful USD 22 million / DKK 143 million follow-on offering for Zealand Pharma

Bryan, Garnier & Co annouces the successful closing of Soitec’s €75.4 million Rights Issue

Bryan, Garnier & Co announces a €14.7m follow-on offering for Amoeba on Euronext with demand from European and US investors

Bryan Garnier & Co advises GeNeuro on its Euronext IPO, raising €33 million, acting as Global Coordinator & Joint Bookrunner

Bryan Garnier & Co advises DBV Technologies on its follow-on offering, raising $281.5m in July 2015, acting as financial advisor

Bryan, Garnier & Co announces the successful €13.2m Euronext IPO of Amoéba

Bryan, Garnier & Co announces the successful $100m Nasdaq IPO of Celyad.

Bryan, Garnier & Co announces that the total proceeds of Galapagos IPO on Nasdaq, the largest Nasdaq IPO of a European biotech, have been raised to $317m following the full exercise of over-allotment option.

Bryan, Garnier & Co announces the successful follow-on offering of £20m for Advanced Oncotherapy plc

Bryan, Garnier & Co announces the successful IPO of Bone Therapeutics.

Bryan, Garnier & Co announces the IPO of Quantum Pharma on London AIM

Bryan, Garnier & Co acts as Global Coordinator and Bookrunner of a Follow-on Offering of €30m for Erytech Pharma

Bryan, Garnier & Co acts as Joint Lead Manager and Joint Bookrunner of DBV $133m IPO on NASDAQ.

Bryan, Garnier & Co advises Voltalia on its transfert to Euronext and €100m Capital Increase

Bryan, Garnier & Co acts as Lead Manager and Sole Bookrunner on ASK’s EUR 22m IPO on Euronext

Bryan, Garnier & Co acts as co-manager of LDR 97m$ follow-on offering on NASDAQ.

Bryan, Garnier & Co acts as Joint Manager and Bookrunner on Genomic Vision €26.4 m Euronext IPO, 4.7x oversubscribed

Bryan, Garnier & Co acts as Lead Manager and Sole Bookrunner on Mcphy Energy’s € 32M Euronext IPO, 8.6x Oversubscribed.

Bryan, Garnier & Co Acts as Joint Lead Manager and Joint Bookrunner of LDR Holding $86M IPO on NASDAQ

Bryan, Garnier & Co announces the success of the IPO of Erytech with a Capital Increase of €28 Million

Bryan, Garnier and Co advised Santen Pharmaceutical Co. Ltd. on its successful takeover of Novagali Pharma S.A.

Bryan, Garnier & Co advises Cellectis on its acquisition of Cellartis and EUR 50 million capital increase

Success of the initial public offering of Leadmedia Group with a total of €12.5 million raised

Great success of Groupe Concoursmania’s IPO, offering 3.5x oversubscribed

Success of the initial public offering of Zealand Pharma

Bryan, Garnier & Co successfully leads a follow-on offering with rights for Valtech

Bryan, Garnier & Co successfully leads Novagali Pharma €22m IPO

Bryan, Garnier & Co leads a Eur 152m capital increase for Transgene

Bryan, Garnier & Co successfully leads €6.7 million IPO for Integragen

Bryan, Garnier & Co leads a € 15,6 m capital increase for ExonHit Therapeutics

Bryan, Garnier & Co has successfully advised majority shareholder GRED in the public tender offer & squeeze out of Softway Medical

Bryan, Garnier & Co. announces it has advised ExonHit Therapeutics on the free allocation of subscription warrants to all its shareholders

Bryan, Garnier & Co. announces successful admission of ONI BioPharma Inc.’s common stock to listing and trading on NYSE Alternext Paris